Type
. A serological test for leprosy based on competitive inhibition of monoclonal antibody binding to the MY2a determinant of Mycobacterium leprae. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1983;77(6):869-71.
Type
. The chemotherapy of leprosy. Progress in medicinal chemistry. 1983;20:1-81.
Type
. Suppressor cells of mouse and man. What is the evidence that they contribute to the aetiology of the mycobacterioses?. Leprosy review [Internet]. 1982;53(4):306-12. Available from: http://leprev.ilsl.br/pdfs/1982/v53n4/pdf/v53n4a10.pdf
Type
. T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Immunology. 1982;47(4):589-95.
Type
. Treatment of sulphone resistant leprosy--a review of sixty one cases. Leprosy in India. 1982;54(4):639-47.
Type
. Composite skin contact smears in multibacillary leprosy patients. Leprosy in India. 1982;54(4):605-12.
Type
. SDS-PAGE analysis of M. leprae protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Clinical and experimental immunology. 1982;49(3):523-31.
Type
. Chemotherapy of leprosy. Lancet (London, England). 1982;2(8296):490.
Type
. In vitro stimulation of lymphocytes in leprosy patients, healthy contacts of leprosy patients, and subjects not exposed to leprosy. Comparison of an antigen fraction prepared from Mycobacterium leprae and tuberculin-purified protein derivative. Scandinavian journal of immunology. 1982;16(2):103-15.
Type
Chemotherapy of leprosy. Lancet (London, England). 1982;2(8289):77-80.